To establish the clinical relevance of RACK1 expression in imatinib resistance, we assessed RACK1 expression in 13 GIST patients who had paired tumor specimens available from before and after imatinib treatment (primary vs. relapsed lesions). Here, RACK1 is linked to gastrointestinal stromal tumor.